luxturna
(voretigene neparvovec-rzyl)Spark Therapeutics, Inc.
Usage: LUXTURNA (voretigene neparvovec-rzyl) is indicated for treating patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy, provided they have viable retinal cells as determined by their physician.